Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pdl Biopharma Inc (PDLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 503,842
  • Shares Outstanding, K 154,080
  • Annual Sales, $ 244,300 K
  • Annual Income, $ 63,610 K
  • 36-Month Beta 0.49
  • Price/Sales 2.06
  • Price/Cash Flow 7.89
  • Price/Book 0.64

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.77 +14.44%
on 08/23/17
3.37 -5.93%
on 09/19/17
+0.37 (+13.21%)
since 08/22/17
3-Month
2.15 +47.44%
on 08/03/17
3.37 -5.93%
on 09/19/17
+0.71 (+28.86%)
since 06/22/17
52-Week
1.93 +64.25%
on 12/20/16
3.77 -15.92%
on 11/15/16
-0.18 (-5.37%)
since 09/22/16

Most Recent Stories

More News
ProQR's Genetic Disorder Candidate Gets Orphan Drug Status

ProQR Therapeutics (PRQR) announced that its investigational dystrophic epidermolysis bullosa candidate, QR-313, was granted orphan drug designation by the FDA.

PDLI : 3.17 (-3.06%)
PRQR : 6.20 (+7.83%)
REGN : 432.72 (-0.17%)
ALXN : 142.82 (-0.07%)
Should Value Investors Consider PDL BioPharma, Inc. (PDLI) Stock?

PDL BioPharma is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

PDLI : 3.17 (-3.06%)
Pluristem's Ischemia Candidate Gets Fast Track Designation

Pluristem Therapeutics' (PSTI) phase III study of PLX-PAD cells in patients with critical limb ischemia granted Fast Track designation by the FDA.

PDLI : 3.17 (-3.06%)
REGN : 432.72 (-0.17%)
PSTI : 1.54 (-1.28%)
ALXN : 142.82 (-0.07%)
PDL BioPharma Updates Presentation Time for Cantor Fitzgerald Conference

PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's chief executive officer, will present at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York City...

PDLI : 3.17 (-3.06%)
3 Pharma/Biotech Sector Bargains for a Healthy Portfolio

The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead....

PDLI : 3.17 (-3.06%)
JAZZ : 147.89 (+0.07%)
GRFS : 20.98 (+1.06%)
GILD : 83.27 (+0.79%)
KITE : 179.30 (-0.04%)
Biotech Stocks on Investors' Radar -- PDL BioPharma, Progenics Pharma, Agenus, and Aptose Biosciences

If you want a Stock Review on PDLI, PGNX, AGEN, or APTO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Monday, September 11, 2017, US markets...

AGEN : 4.10 (unch)
PDLI : 3.17 (-3.06%)
PGNX : 6.96 (unch)
APTO : 1.62 (unch)
PDL BioPharma to Present at Two Upcoming Investor Conferences

PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will present at two investor conferences in September.

PDLI : 3.17 (-3.06%)
5 Best Performing Stocks of August

Markets traversed a month characterized by turbulence but ultimately closed in the green.

SUMR : 1.95 (+1.56%)
AAPL : 151.89 (-0.98%)
KEM : 19.71 (+0.20%)
PDLI : 3.17 (-3.06%)
JPM : 94.83 (-0.21%)
JOUT : 66.64 (+1.14%)
MMM : 210.76 (+0.15%)
GS : 231.03 (-0.11%)
ZAGG : 14.30 (+0.70%)
BA : 256.45 (+0.16%)
Why PDL BioPharma (PDLI) Could Be Positioned for a Surge

PDL BioPharma, Inc. (PDLI) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.

PDLI : 3.17 (-3.06%)
Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash

Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash

SUMR : 1.95 (+1.56%)
IPI : 4.03 (+0.25%)
ITCI : 19.29 (+0.21%)
PDLI : 3.17 (-3.06%)
CGNT : 2.65 (+1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital...

See More

Support & Resistance

2nd Resistance Point 3.36
1st Resistance Point 3.26
Last Price 3.17
1st Support Level 3.09
2nd Support Level 3.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.